$0.01 EPS Expected for Genomic Health, Inc. (GHDX)

October 29, 2017 – By Darrin Black

Investors sentiment increased to 1.66 in 2017 Q2. Its up 0.56, from 1.1 in 2017Q1. It improved, as 6 investors sold Genomic Health, Inc. shares while 32 reduced holdings. 11 funds opened positions while 52 raised stakes. 30.55 million shares or 1.09% more from 30.22 million shares in 2017Q1 were reported.
131,935 are owned by Motley Fool Asset Mngmt Lc. First Advisors Limited Partnership holds 0% or 33,949 shares in its portfolio. Great West Life Assurance Can accumulated 927 shares or 0% of the stock. Geode Management Ltd Liability accumulated 205,713 shares. Art Llc invested in 8,478 shares. Motley Fool Wealth Mngmt Ltd Liability owns 140,481 shares. Northern Tru accumulated 275,818 shares or 0% of the stock. California Public Employees Retirement Sys holds 62,500 shares or 0% of its portfolio. American Intll Gp holds 0% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX) for 12,251 shares. Barclays Public Ltd Com accumulated 0% or 2,182 shares. Voya Investment Limited Liability Company holds 8,622 shares or 0% of its portfolio. First Comml Bank Of Omaha stated it has 25,330 shares. Legal General Gp Pcl owns 6,932 shares. Dekabank Deutsche Girozentrale holds 0% or 17,300 shares. Natl Bank Of Montreal Can reported 0% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX).

Since May 3, 2017, it had 0 buys, and 7 insider sales for $1.62 million activity. 5,000 shares valued at $146,981 were sold by Shak Steven on Tuesday, May 23. 5,000 shares were sold by Cole G Bradley, worth $158,342 on Tuesday, June 13. Another trade for 5,000 shares valued at $158,849 was sold by Popovits Kimberly J.

Investors wait Genomic Health, Inc. (NASDAQ:GHDX) to report on November, 7. its quarterly earnings Wall Street analysts expect $0.01 EPS, up $0.09 or 112.50 % from last year’s $-0.08 same quarter earnings. This translates into $345,033 profit for GHDX giving the stock a 840.50 P/E. This is assuming the current $0.01 EPS is accurate. Genomic Health, Inc.’s Wall Street analysts see -112.50 % EPS growth, taking into account the $-0.08 EPS reproted in the previous quarter, The stock increased 2.06% or $0.68 on October 27, reaching $33.62. About 123,915 shares traded. Genomic Health, Inc. (NASDAQ:GHDX) has risen 23.46% since October 29, 2016 and is uptrending. It has outperformed by 6.76% the S&P500.

Genomic Health, Inc. (NASDAQ:GHDX) Ratings Coverage

Among 8 analysts covering Genomic Health (NASDAQ:GHDX), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Genomic Health had 24 analyst reports since August 5, 2015 according to SRatingsIntel. Piper Jaffray downgraded the stock to “Neutral” rating in Monday, January 11 report. The stock has “Market Perform” rating by Raymond James on Friday, August 28. Jefferies maintained Genomic Health, Inc. (NASDAQ:GHDX) on Friday, October 20 with “Hold” rating. Jefferies maintained the stock with “Hold” rating in Wednesday, August 17 report. The company was upgraded on Monday, August 24 by Zacks. UBS upgraded the shares of GHDX in report on Monday, November 23 to “Buy” rating. The company was upgraded on Wednesday, November 4 by Raymond James. Jefferies maintained Genomic Health, Inc. (NASDAQ:GHDX) on Monday, June 12 with “Hold” rating. The stock of Genomic Health, Inc. (NASDAQ:GHDX) earned “Underweight” rating by Barclays Capital on Wednesday, September 2. The firm has “Buy” rating by Canaccord Genuity given on Monday, August 14.

Genomic Health, Inc. is a healthcare firm that provides genomic diagnostic tests to personalize cancer treatment. The company has market cap of $1.16 billion. The Firm develops and commercializes genomic clinical laboratory services. It currently has negative earnings. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

More notable recent Genomic Health, Inc. (NASDAQ:GHDX) news were published by: Zacks.com which released: “Genomic Health Ties up With Biocartis, Boosts Oncotype DX” on September 14, 2017, also Seekingalpha.com with their article: “Genomic Health’s (GHDX) CEO Kim Popovits on Q1 2017 Results – Earnings Call …” published on May 13, 2017, Fool.com published: “3 Things Investors Should Know About Genomic Health Stock” on May 30, 2017. More interesting news about Genomic Health, Inc. (NASDAQ:GHDX) were released by: Nasdaq.com and their article: “Genomic Health Cancer Tests Strong, Operating Expenses a Woe” published on June 21, 2017 as well as Zacks.com‘s news article titled: “Genomic Health to Unveil Oncotype DX Study Results at ASCO” with publication date: June 01, 2017.